Wegovy (semaglutide 2.4 mg weekly) vs. Ozempic (semaglutide 0.5–1 mg weekly)
| Feature | Wegovy | Ozempic |
|---|---|---|
| Label indication | Chronic weight management in adults with a BMI ≥ 30 kg/m² (or ≥ 27 kg/m² with ≥ 1 weight‑related comorbidity) | Type 2 diabetes mellitus (also approved for weight loss in some countries, but the label focus is glucose control) |
| Dose | 2.4 mg once per week (after a titration period) | 0.5 mg once per week → can be titrated to 1 mg once per week (sometimes 2 mg in certain regions) |
| Primary therapeutic goal | Sustained weight loss (average ≈ 15 % of initial body weight over 68 weeks) | Reduce HbA1c, fasting plasma glucose, and support weight loss as a secondary benefit |
| Effect on blood glucose / HbA1c | Minimal, clinically insignificant effect. In the SELECT trial, the mean HbA1c change was ~–0.2 % (±0.5 %) in patients who had baseline diabetes. Fasting glucose fell by ~15–20 mg/dL in a subset of pre‑diabetics/diabetics, but this was not a primary endpoint and the reduction was modest. | Significant, clinically meaningful reduction. Typical HbA1c decreases are 1–1.5 % (0.5 %‑1 % per 0.5 mg dose; 1 %‑1.5 % per 1 mg dose) with corresponding reductions in fasting plasma glucose of 30–50 mg/dL. These numbers come from multiple phase III trials (SUSTAIN series) and real‑world studies. |
| Mechanism relevant to glucose | GLP‑1 receptor agonist → ↑ insulin secretion, ↓ glucagon, slowed gastric emptying. At the 2.4 mg dose used for weight loss, the receptor occupancy is high enough for appetite suppression and weight loss, but the glucose‑lowering effect is smaller than at the lower doses used for diabetes. | Same mechanism, but at lower doses (0.5–1 mg) the drug’s primary action is to lower glucose; the weight‑loss benefit is a secondary, but still clinically relevant, effect. |
| Clinical implications | Not approved for diabetes; if you’re taking Wegovy and you’re also diabetic, you’ll still need a dedicated diabetes medication to achieve the glucose‑lowering targets. The weight loss from Wegovy can indirectly improve insulin sensitivity over time, but it’s not a substitute for a glucose‑lowering agent. | Can be prescribed for both glucose control and weight management. Many patients with type 2 diabetes see substantial weight loss (≈ 4–5 % of body weight) along with HbA1c reductions. |
| Side‑effect profile related to glucose | GI side‑effects (nausea, vomiting, diarrhea) are common. Hypoglycemia is rare unless the patient is on other glucose‑lowering agents. | Same GI side‑effects. Hypoglycemia can occur when combined with sulfonylureas or insulin, but is uncommon when used as monotherapy. |
Bottom line
- Ozempic is a glucose‑lowering drug that reliably reduces HbA1c by 1–1.5 % and fasting glucose by 30–50 mg/dL.
- Wegovy is a weight‑loss drug; its effect on HbA1c is small (~0.2 % reduction) and not clinically significant for diabetes management.
- If you’re diabetic and looking for weight loss, Ozempic (or its equivalents) is the drug that addresses both needs.
- If you’re not diabetic but need weight loss, Wegovy is appropriate; you’ll still need a separate diabetes medication if you develop glucose intolerance.
Disclaimer: This information is for general educational purposes only. It is not a substitute for personalized medical advice. If you have questions about how either medication might fit into your treatment plan, discuss them with your prescribing clinician.